Literature DB >> 2952281

Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: mechanisms of activation and killing.

S Ozaki, J York-Jolley, H Kawamura, J A Berzofsky.   

Abstract

Myoglobin-specific, Iad-restricted cloned helper T cells and T hybridomas were found to directly kill Iad-bearing, myoglobin-pulsed B lymphoma targets and could also kill bystander targets, but only in the presence of antigen-pulsed antigen presenting cells (APC). The induction of the killing requires recognition of processed antigen in the context of class II major histocompatibility complex (MHC) molecules. Despite the specificity of induction, the bystander killing suggests a nonspecific lytic mechanism. The direct killing can be inhibited only by cold specific targets, whereas the bystander killing can be blocked by both specific and nonspecific targets. The cold target inhibition seems to be due to interference with effector-to-target contact or proximity rather than due to high-dose suppression of T-cell activation. Experiments using T-cell supernatants or cyclosporin A suggested that the helper T cells kill targets by synthesizing short-range soluble factor(s) with nonspecific killing activity de novo during the effector phase, but only while antigen-specific signal transduction is occurring. The mechanism of cold target inhibition appears to be absorption or consumption of a short-acting cytotoxic lymphokine by cells which must be able to interact closely with the effector cell. Normal spleen B cells, despite their capability for activating the helper T cells, cannot inhibit specific killing or be killed by helper T cells, even after lipopolysaccharide stimulation. Thus, although killing by helper T cells may play a negative feedback role in the normal immune response, our data raise the possibility that the helper T-cell-mediated killing may contribute to the immune surveillance against malignancy by virtue of the preferential killing of tumor cells either directly or indirectly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952281     DOI: 10.1016/0008-8749(87)90079-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Induction of autoreactive CD8+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Robert S Fujinami
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Genetic restriction of protective immunity to Plasmodium yoelii sporozoites.

Authors:  W R Weiss; M F Good; M R Hollingdale; L H Miller; J A Berzofsky
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

3.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 4.  Structural basis of antigen recognition by T lymphocytes. Implications for vaccines.

Authors:  J A Berzofsky
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Class II-restricted bifunctional T-cell hybridomas reactive to self- and foreign myelin basic protein.

Authors:  D C Rayner; L D Petrycky
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

6.  Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors.

Authors:  S M Lonning; W Zhang; S R Leib; T C McGuire
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Immunohistological analysis of anti-melanoma host responses.

Authors:  R Strohal; K Marberger; H Pehamberger; G Stingl
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

8.  Biological response modifiers (BRM) as antigens. III. T cell lines specific for BRM kill tumor cells in a BRM-specific manner.

Authors:  S Ozaki; T Okazaki; K Nakao
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 9.  Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

Authors:  G L Beatty; Y Paterson
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.